$SXTP News

60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027

60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?

60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6

60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Q2 EPS $(0.90) Misses $(0.86) Estimate, Sales $56.798K Miss $186.000K Estimate

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals Announces $1M Private Placement Of 574,713 Shares At $1.74, Including Warrants

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

60 Degrees Pharmaceuticals Will Be Issued US Patent Number 12,691,107 Tomorrow Titled "METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE".

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

60 Degrees Pharmaceuticals Enters Exclusive Option Agreement With Florida State's Research Foundation Regarding IP To Develop Castanospermine For Multiple Tick-Borne Diseases

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

60 Degrees Pharma's B-Free Babesiosis Trial Clears Initial Safety Review, Advances After DSMB Recommendation

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharma Executes Patent Licensing Agreement With Florida State University To Commence Large-Scale Production Techniques To Extract, Purify Castanospermine From Seeds Of Australian Chestnut For Non-Prescription Uses